Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: The PERF study

Bone

Volumn 34, Issue 4, 2004, Pages 728-735

  Bagger, Yu Z ^a   Tankó, László B ^a   Alexandersen, Peter ^a   Hansen, Henrik Bo ^a   Møllgaard, Anette ^a   Ravn, Pernille ^a   Qvist, Per ^b   Kanis, John A ^c   Christiansen, Claus ^a  

^a CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^b NORDIC BIOSCIENCE A S   (Denmark)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

BMD; Fractures; Limited HRT; Postmenopausal osteoporosis; Withdrawal effect

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CYPROTERONE ACETATE; ESTRADIOL; GESTAGEN; HORMONE; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; PIPERAZINE ESTRONE SULFATE; PLACEBO; PROGESTERONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; ARTICLE; BONE DENSITY; BONE MASS; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FRAGILITY FRACTURE; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; RADIOLOGY; VERTEBRA FRACTURE;

AGED; BONE DENSITY; ESTROGEN REPLACEMENT THERAPY; FEMALE; FOLLOW-UP STUDIES; FRACTURES, BONE; HUMANS; MIDDLE AGED; OSTEOPOROSIS; TIME FACTORS;

EID: 1642367713     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2003.12.021     Document Type: Article

References (30)

1. Kanis J.A., Melton L.J. III, Christiansen C., Johnston C.C., Khaltaev N. The diagnosis of osteoporosis. J. Bone Miner. Res. 9:1994;1137-1141.
2. Seeley D.G., Browner W.S., Nevitt M.C., Genant H.K., Scott J.C., Cummings S.R. Which fractures are associated with low appendicular bone mass in elderly women? The Study of Osteoporotic Fractures Research Group. Ann. Intern. Med. 115:1991;837-842.
3. Barrett-Connor E. The economic and human costs of osteoporotic fracture. Am. J. Med. 98:1995;3S-8S.
4. Weiss N.S., Ure C.L., Ballard J.H., Williams A.R., Daling J.R. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N. Engl. J. Med. 303:1980;1195-1198.
5. Kiel D.P., Felson D.T., Anderson J.J., Wilson P.W., Moskowitz M.A. Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study. N. Engl. J. Med. 317:1987;1169-1174.
6. Cauley J.A., Seeley D.G., Ensrud K., Ettinger B., Black D., Cummings S.R. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann. Intern. Med. 122:1995;9-16.
7. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.Let al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 288:2002;321-333.
8. Christiansen C., Christensen M.S., Transbol I. Bone mass after withdrawal of oestrogen replacement. Lancet. 1:1981;1053-1054.
9. Lindsay R., Hart D.M., MacLean A., Clark A.C., Kraszewski A., Garwood J. Bone response to termination of oestrogen treatment. Lancet. 1:1978;1325-1327.
10. Tremollieres F.A., Pouilles J.M., Ribot C. Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women. Osteoporos. Int. 12:2001;385-390.
11. Greendale G.A., Espeland M., Slone S., Marcus R., Barrett-Connor E. Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study. Arch. Intern. Med. 162:2002;665-672.
12. Riis B.J., Johansen J., Christiansen C. Continuous oestrogen-progestogen treatment and bone metabolism in post-menopausal women. Maturitas. 10:1988;51-58.
13. Riis B.J., Jensen J., Christiansen C. Cyproterone acetate, an alternative gestagen in postmenopausal oestrogen/gestagen therapy. Clin. Endocrinol. (Oxf.). 26:1987;327-334.
14. Riis B.J., Thomsen K., Strom V., Christiansen C. The effect of percutaneous estradiol and natural progesterone on postmenopausal bone loss. Am. J. Obstet. Gynecol. 156:1987;61-65.
15. Marslew U., Overgaard K., Riis B.J., Christiansen C. Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding. Obstet. Gynecol. 79:1992;202-210.
16. Marslew U., Munk-Nielsen N., Nilas L., Riis B.J., Christiansen C. Bleeding pattern and climacteric symptoms during different sequential combined HRT regimens in current use. Maturitas. 19:1994;225-237.
17. Alexandersen P., Byrjalsen I., Christiansen C. Piperazine oestrone sulphate and interrupted norethisterone in postmenopausal women: effects on bone mass, lipoprotein metabolism, climacteric symptoms, and adverse effects. BJOG. 107:2000;356-364.
18. Bjarnason N.H., Byrjalsen I., Hassager C., Haarbo J., Christiansen C. Low doses of estradiol in combination with gestodene to prevent early postmenopausal bone loss. Am. J. Obstet. Gynecol. 183:2000;550-560.
19. Borg J., Mollgaard A., Riis B.J. Single X-ray absorptiometry: performance characteristics and comparison with single photon absorptiometry. Osteoporos. Int. 5:1995;377-381.
20. Johnell O., Kanis J.A., Oden A., Redlund-Johnell I., Hasserius R., Sernbo I.et al. Targeting of hormone replacement therapy immediately after menopause. Bone. 28:2001;440-445.
21. Cauley J.A., Zmuda J.M., Ensrud K.E., Bauer D.C., Ettinger B. Timing of estrogen replacement therapy for optimal osteoporosis prevention. J. Clin. Endocrinol. Metab. 86:2001;5700-5705.
22. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B.et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA. 280:1998;605-613.
23. Schneider D.L., Barrett-Connor E.L., Morton D.J. Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study. JAMA. 277:1997;543-547.
24. Randell K.M., Honkanen R.J., Kroger H., Saarikoski S. Does hormone-replacement therapy prevent fractures in early postmenopausal women? J. Bone Miner. Res. 17:2002;528-533.
25. Kanis J.A., Johnell O., Gullberg B., Allander E., Dilsen G., Gennari C. et al. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. BMJ. 305:1992;1124-1128.
26. Felson D.T., Zhang Y., Hannan M.T., Kiel D.P., Wilson P.W., Anderson J.J. The effect of postmenopausal estrogen therapy on bone density in elderly women. N. Engl. J. Med. 329:1993;1141-1146.
27. Devine A., Dick I.M., Heal S.J., Criddle R.A., Prince R.L. A 4-year follow-up study of the effects of calcium supplementation on bone density in elderly postmenopausal women. Osteoporos. Int. 7:1997;23-28.
28. Shiraki M., Ito H., Orimo H. The ultra long-term treatment of senile osteoporosis with 1 alpha-hydroxyvitamin D3. Bone Miner. 20:1993;223-234.
29. Jonsson B., Kanis J., Dawson A., Oden A., Johnell O. Effect and offset of effect of treatments for hip fracture on health outcomes. Osteoporos. Int. 10:1999;193-199.
30. Caulin F., Kanis J.A., Johnell O., Oden A. Optimal age for preventing osteoporosis after menopause depends on effects of stopping treatment. Bone. 30:2002;754-758.